Post by Deleted on Jul 2, 2021 21:47:07 GMT -5
I'm in OCGN currently. I was previously in BNGO and sold it, next week I will probably buy it again.
BNGO - Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-sI'm currently in OCGN and will buy BNGOpecific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Here are 2 recent positive articles:
Bionano Genomics Stock Has Short-Term Opportunities : INVESTORPLACE • 4 DAYS AGO
BNGO Stock: 2 Big Reasons Bionano Genomics Fans Should Be Cheering : INVESTORPLACE • 4 DAYS AGO
www.nasdaq.com/market-activity/stocks/bngo
______________________________________________________________________________________________________________________________________
OCGN - Entered the Vaccine business months ago and they claim they have an excellent cure/aid rate/percentage.
Their main business is Ocugen Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Its product candidate includes OCU200 and OCU300 to treat diabetes.
They caame out with this news, below, Friday AH and the stock went up $1.
July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday. (Reporting by Dania Nadeem in Bengaluru; Editing by Ramakrishnan M.) ((Dania.Nadeem@thomsonreuters.com;)) Keywords: HEALTH CORONAVIRUS/OCUGEN COVAXIN (URGENT).
They are partners with Bharat Biotech in the Vaccine aid/cure, OCGN gets 45% of profits partner Bharat Biotech gets 55% of profits.
Twice in the last year it has gone into the mid teens and crashed. The latest downtrend from $16 happened because they didn't get Early Approval afor their Vaccine from the fD and the stock came down From $16. They met with the FDA and decided to go through regular approval.
www.nasdaq.com/articles/ocugen-says-indian-partners-vaccine-93.4-effective-against-severe-covid-19-2021-07-02
BNGO - Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-sI'm currently in OCGN and will buy BNGOpecific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Here are 2 recent positive articles:
Bionano Genomics Stock Has Short-Term Opportunities : INVESTORPLACE • 4 DAYS AGO
BNGO Stock: 2 Big Reasons Bionano Genomics Fans Should Be Cheering : INVESTORPLACE • 4 DAYS AGO
www.nasdaq.com/market-activity/stocks/bngo
______________________________________________________________________________________________________________________________________
OCGN - Entered the Vaccine business months ago and they claim they have an excellent cure/aid rate/percentage.
Their main business is Ocugen Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Its product candidate includes OCU200 and OCU300 to treat diabetes.
They caame out with this news, below, Friday AH and the stock went up $1.
July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday. (Reporting by Dania Nadeem in Bengaluru; Editing by Ramakrishnan M.) ((Dania.Nadeem@thomsonreuters.com;)) Keywords: HEALTH CORONAVIRUS/OCUGEN COVAXIN (URGENT).
They are partners with Bharat Biotech in the Vaccine aid/cure, OCGN gets 45% of profits partner Bharat Biotech gets 55% of profits.
Twice in the last year it has gone into the mid teens and crashed. The latest downtrend from $16 happened because they didn't get Early Approval afor their Vaccine from the fD and the stock came down From $16. They met with the FDA and decided to go through regular approval.
www.nasdaq.com/articles/ocugen-says-indian-partners-vaccine-93.4-effective-against-severe-covid-19-2021-07-02
